Skip to content

About Us

Microfluidic Licensing Opportunities

Caliper's portfolio of microfluidics-related patents has been ranked as high as #2 in technological strength in the Biotech/Pharma sector of the MIT Technology Review Patent Scorecard1. Caliper actively out-licenses this portfolio as part of its Caliper Driven™ program to broaden and accelerate the availability of new technologies and products for life science and diagnostics applications. Licensing Caliper's microfluidic intellectual property benefits our partners by enhancing the strength of their product and service offerings through the incorporation of our technology.

  1. MIT Technology Review, May, 2004

Licensees of our microfluidic patent estate include:



Affymetrix, Inc.



Affymetrix 

Agilent Technologies, Inc.



Agilent 

Canon US Life Scieneces, Inc.



Canon US Life Sciences Inc


Wako PUre Chemical Industries, Ltd. 


Wako 


Imaging Technology

Xenogen Corporation holds the exclusive license under U.S. patent numbers 5,650,135; 6,217,847; 6,649,143; 6,890,515; 6,908,605; 6,916,462; 6,923,951; 6,939,533; 7,198,774; 7,255,851 and other pending applications relating to methods of non-invasive, biophotonic imaging across a wide range of wavelengths and specifically including light generated by bioluminescence and fluorescence. Purchasers of Xenogen's imaging systems typically require sublicenses to practice the technology covered by these patents, which are necessary for the practice of biophotonic imaging. Patents are pending worldwide for this technology, and have already issued in the European Union, Japan, the People's Republic of China, and other countries. Xenogen owns other patents related to sepsis models, expression cassettes for creating light-generating bacteria, and biophotonic methods for screening angiogenesis modulating compounds. Access to those proprietary patented in vivo biophotonic imaging technologies and associated biological products is available only through a commercial-use license or academic license from Xenogen Corporation.

Certain of Xenogen’s LPTA® animal model lines and Bioware® cell lines are produced under licenses from Promega Corporation and The Regents of the University of California. Please see the applicable product page for a description of the terms of purchase.


Transgenic Technology

Xenogen Biosciences holds a license under several technologies for producing genetically engineered animals:

  • U.S. Patent Nos. 6,689,610, 6,204,061, 5,631,153, 5,627,059, 5,487,992, and 5,464,764 relating to “Positive-Negative Selection Methods and Vectors,” which improves efficiency of the production of gene-targeted research animals relating to genetically engineering "knock-out" research animals.
  • U.S. Patent Nos. 6,638,768, 6,528,313 and 6,528,314 relating to methods of genetically engineering "knock-in" research animals.
  • U.S. Patent Nos. 5,654,182, 5,677,177 and 5,885,836 relating to methods of genetically engineering "conditional" research animals using flp-frt.

 

Inquiries

Inquiries regarding additional information on licensing of any Caliper technologies should be e-mailed to bd@caliperls.com.